Genesis has partnered with multiple industry leaders to amplify the impact of our AI platform for drug discovery. Combining GEMS with the drug development prowess of our partners, we aim to further accelerate impact for patients.
In 2025, Genesis partnered with Incyte to leverage GEMS for Incyte-selected targets. Genesis and Incyte will collaborate on two initial targets, and the agreement included a $30 million upfront payment to Genesis.
In 2024, Genesis partnered with Gilead to deploy GEMS against multiple hard-to-drug targets. Genesis received $35 million in upfront payment to collaborate on 3 initial targets.
Using GEMS to generate and optimize first- or best-in-class small molecules for difficult biological targets, which offer potential to advance the treatment of difficult cancers.
Late Lead Optimization
PIK3CA is a common oncogenic driver in breast and colorectal cancers. Genesis is advancing multiple lead molecules and approaching development candidate nomination for highly potent and selective pan-mutant allosteric inhibitors of PIK3CA.
Lead Optimization
Genesis is optimizing small molecules that aim to leverage tumor mutational burden and ultimately overcome limited response to checkpoint inhibitors.
Discovery
Genesis is generating small molecules to inhibit an important anti-apoptotic regulator of the extrinsic cell death pathway, which could prevent evasion of apoptosis in cancer cells with this dependency.
Using GEMS to generate and optimize first-in-class small molecules for well-validated targets, as well as novel immunology targets.
Discovery
Many targets for autoimmune disorders have proven efficacy from approved or clinical stage biologics, but have yet to be drugged with small molecules. Genesis has multiple programs generating small molecules to inhibit such well-validated targets, to offer oral treatment options to patients in need.
Lead Optimization
Genesis is developing small molecule inhibitors targeting a protein central to several inflammatory signaling pathways, aiming to meet the unmet needs of patients with autoimmune diseases
Genesis Scientists
At Genesis, leading AI researchers team with world-class drug hunters to develop and deploy GEMS for our partnered and wholly owned pipeline of cutting-edge medicines. Our AI research is based in the Bay Area and New York City, with our wet lab in San Diego. Our team seamlessly works across disciplines internally and as forward-deployed engineers (FDE’s) in our large pharma partnerships.
